Inhibition of alternative immune checkpoint molecules is being explored to enhance immunostimulatory and antitumor activity in DLBCL, most notably T‐cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte‐activated gene‐3 (LAG‐3), and T‐cell immunoglobulin and mucin‐containing protein‐3 (TIM‐3), all of which mediate suppression of T‐cell activation. Here, LAG3 is linked to diffuse large B-cell lymphoma.